Mineralys’ shares got a more than 50% boost Monday morning as new data showed its hypertension drug reduced blood pressure in ...
Protagonist Therapeutics notches a milestone in its pact with Takeda for rusfertide. New data show that many patients with a ...
BullFrog AI plans to introduce what it considers a game-changing approach that could shorten timelines, reduce costs, and increase success rates in drug development.
Pheiron and Ribo are excited to announce that the first two strategic collaboration milestones have been successfully ...
Merck’s oral TLR7/8 inhibitor enpatoran has failed to meet the primary endpoint in a subgroup of patients, but development of ...
Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...
The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...
The investment of over $6 million will expand LGM Pharma’s Rosenberg, Texas manufacturing facility as part of its Phase I ...
In regard to what’s happening now with NIH, the main thing to do is diversify. You raise both non-dilutive funding through ...
Patients enroll in phase 2 oncology trials seeking access to promising new treatments, but the risk-benefit assessments and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback